ClinicalTrials.gg
CompletedNCT07162077Updated Sep 10, 2026

Etch-bleach-seal Technique in Managing Opacities Related MIH Using Icon®

An interventional study of Sodium hypochlorite 5.25% and ICON resin infiltration Material group in vivo in Molar Incisor Hypomineralisation, sponsored by Latakia University. Completed at 1 site in Syria. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Latakia University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Sex
All
01

Study summary

Objectives: to compare aesthetic effectiveness of resin infiltration with/without using sodium hypochlorite in managing opacities of MIH on incisors, and to compare parent's satisfaction with results of both application protocols.

Methods: Twenty-four teeth with yellow/ brown opacities of MIH, will be diagnosed according to EAPD diagnostic criteria, will be randomly allocated to test or control group. In the test group, the investigators will be applied sodium hypochlorite 5.25% by using cotton wad before treatment, then after the first and second etching cycles (application of the Icon-Etch (ICON® -Etch; DMG, Hamburg, Germany) and Icon-dry (ICON® -Dry; DMG, Hamburg, Germany) according to the manufacturer's recommendations) as irrigation step and following the third -Etch etching cycle Icon-infiltrant (ICON® -Infiltrant; DMG, Hamburg, Germany) will be applied . In control group, the investigators will be applied the same protocol of test group but without using sodium hypochlorite. The masking efficacy will be analyzed using the Lab System to calculate the color difference (ΔE) between the opacity and the adjacent enamel in Adobe Photoshop 2024. The infiltration proportion of opacity will be measured using Image J software and the infiltrated area will be expressed as a percentage. The satisfaction of the parents with the results of both application protocols will be compared using Likert scale.

02

Conditions studied

  • Molar Incisor Hypomineralisation
03

In context

Molar Hypomineralization

133 studies on the registry are indexed under Molar Hypomineralization; 46 are open to participants now.

This study's enrollment of 15 is below the median of 53 across 104 interventional studies indexed under Molar Hypomineralization.

Browse Molar Hypomineralization studies →

Lead sponsor

Latakia University is the lead sponsor of 20 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with MIH-related opacities on the incisal and middle thirds of the buccal surface of their permanent incisors, ac- cording to EAPD diagnostic criteria of (MIH), only isolated lesions will be selected.

Exclusion criteria

Exclusion Criteria:

  • Teeth with resin composite restorations, previously treated by exter- nal bleaching, micro-abrasion or re-mineralization(fluoride varnish or calcium-based products such asCPP-ACP) will be excluded.
  • Opacities present only on incisors without molar
  • WSLs caused by orthodomtic treatment
  • Teeth affected by dental fluorosis, Amelogenesis imperfecta and Tetracycline-pigmented teeth
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Sodium hypochlorite & ICON

    Resin infitration ( ICON (DMG, Hamburg, Germany)) and sodium hypochlorite 5.25%

    Procedure: Sodium hypochlorite 5.25%

  • Active comparator
    ICON

    Resin infiltration ( ICON (DMG, Hamburg, Germany))

    Procedure: ICON resin infiltration Material group in vivo

Interventions

  • ProcedureSodium hypochlorite 5.25%

    In the test group, the investigators will be applied sodium hypochlorite 5.25% by using cotton wad on the opacity before treatment, then after the first and second etching cycles (application of the Icon-Etch (ICON® -Etch; DMG, Hamburg, Germany) and Icon-dry (ICON® -Dry; DMG, Hamburg, Germany) according to the manufacturer's recommendations) as irrigation step and following the third -Etch etching cycle Icon-infiltrant (ICON® -Infiltrant; DMG, Hamburg, Germany) will be applied.

  • ProcedureICON resin infiltration Material group in vivo

    In control group, the investigators will be applied the same protocol of test group but without using sodium hypochlorite

06

What researchers measure

Primary outcomes

  1. Masking efficacy

    The masking efficacy will be analyzed using the Lab System to calculate the color difference (ΔE) between the opacity and the adjacent enamel in Adobe Photoshop 2024.

    Time frame: The masking efficacy will be analyzed on day 1 and (7 - 10) days after day 1

Secondary outcomes

  1. The satisfaction of the parents

    Likert scale

    Time frame: On day 1 and (7-10) days after

07

Study locations

1 site
  • TishreenU
    Latakia, Syria
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Sep 2026, 12 months.

Of 62 non-industry interventional studies with no phase under Molar Hypomineralization, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 12 months is below that.

Counting every sponsor, half of 62 studies reached it within 14 months; a quarter within 8 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 9, 2025
StartActual
Aug 25, 2025
Primary completionActual
Sep 5, 2026
CompletionActual
Sep 5, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07162077
Lead sponsor
Latakia University
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Aug 25, 2025
Primary completion
Sep 5, 2026
Completion
Sep 5, 2026
Last update
Sep 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion